Published in ASAIO J on September 20, 1995
Control of the amplification convertase of complement by the plasma protein beta1H. Proc Natl Acad Sci U S A (1976) 6.65
Diagnostic value of standardized assays for anti-neutrophil cytoplasmic antibodies in idiopathic systemic vasculitis. EC/BCR Project for ANCA Assay Standardization. Kidney Int (1998) 4.31
Analysis of the synovial cell infiltrate in early rheumatoid synovial tissue in relation to local disease activity. Arthritis Rheum (1997) 3.80
Decrease in cellularity and expression of adhesion molecules by anti-tumor necrosis factor alpha monoclonal antibody treatment in patients with rheumatoid arthritis. Arthritis Rheum (1996) 2.96
C3 nephritic factor (C3NeF): stabilization of fluid phase and cell-bound alternative pathway convertase. J Immunol (1976) 2.64
Requirement of extracellular complement and immunoglobulin for intracellular killing of micro-organisms by human monocytes. J Clin Invest (1979) 2.42
Complement in organ transplantation. Contributions to inflammation, injury, and rejection. Transplantation (1995) 2.36
Reduction of synovial inflammation after anti-CD4 monoclonal antibody treatment in early rheumatoid arthritis. Arthritis Rheum (1995) 2.25
Resistance to both complement activation and phagocytosis in type 3 pneumococci is mediated by the binding of complement regulatory protein factor H. Infect Immun (1999) 1.87
The value of indirect immunofluorescence and solid phase techniques for ANCA detection. A report on the first phase of an international cooperative study on the standardization of ANCA assays. EEC/BCR Group for ANCA Assay Standardization. J Immunol Methods (1993) 1.86
The current status of neutrophil cytoplasmic antibodies. Clin Exp Immunol (1989) 1.78
Functional analysis of the classical, alternative, and MBL pathways of the complement system: standardization and validation of a simple ELISA. J Immunol Methods (2004) 1.78
Participation of immunoglobulins and complement components in the intracellular killing of Staphylococcus aureus and Escherichia coli by human granulocytes. Infect Immun (1981) 1.74
Risk factors for deep surgical site infections after spinal fusion. Eur Spine J (2010) 1.70
Aggregated human immunoglobulin G stabilized by albumin: a standard for immune complex detection. J Immunol Methods (1979) 1.60
T cells cloned from human rheumatoid synovial membrane functionally represent the Th1 subset. Scand J Immunol (1992) 1.58
A pathogenic role for secretory IgA in IgA nephropathy. Kidney Int (2006) 1.58
Interaction between human neutrophils and zymosan particles: the role of opsonins and divalent cations. J Immunol (1981) 1.51
C3 requirements for formation of alternative pathway C5 convertase. J Immunol (1976) 1.50
The glomerular deposition of PAS positive material correlates with renal function in human kidney diseases. Clin Nephrol (1997) 1.48
Optimization of the dose of intrathecal morphine in total hip surgery: a dose-finding study. Anesth Analg (1999) 1.48
Characterization of immunogenic properties of haptenated liposomal model membranes in mice. I. Thymus independence of the antigen. Immunology (1979) 1.47
Interleukin-17 activates human renal epithelial cells in vitro and is expressed during renal allograft rejection. J Am Soc Nephrol (1998) 1.47
Bone marrow IgA and IgA subclass synthesis in ankylosing spondylitis. J Rheumatol (1992) 1.47
Antineutrophil cytoplasmic autoantibodies: a review of the antigens involved, the assays, and the clinical and possible pathogenetic consequences. Blood (1993) 1.46
The effect of calcineurin inhibitors and corticosteroids on the differentiation of human dendritic cells. Eur J Immunol (2000) 1.45
Circulating IgA-immune complexes in Henoch-Schönlein purpura. A longitudinal study of their relationship to disease activity and vascular deposition of IgA. Am J Med (1980) 1.44
Antilactoferrin antibodies in patients with rheumatoid arthritis are associated with vasculitis. Arthritis Rheum (1992) 1.44
Human IgA activates the complement system via the mannan-binding lectin pathway. J Immunol (2001) 1.41
Anti-cyclic citrullinated peptide antibodies from rheumatoid arthritis patients activate complement via both the classical and alternative pathways. Arthritis Rheum (2009) 1.40
Isolation of alternative pathway C3 convertase containing uncleaved B and formed in the presence of C3 nephritic factor (C3neF). J Immunol (1976) 1.38
Activation of the alternative pathway of complement by human serum IgA. Eur J Immunol (1987) 1.38
The role of complement in the binding and degradation of immunoglobulin aggregates by macrophages. J Immunol (1979) 1.36
Enhanced degradation of soluble immunoglobulin aggregates by macrophages in the presence of complement. Immunology (1979) 1.35
The value of complement and immune complex determinations in monitoring disease activity in patients with systemic lupus erythematosus. Arthritis Rheum (1985) 1.34
Effect of defensins on interleukin-8 synthesis in airway epithelial cells. Am J Physiol (1997) 1.34
The Addiction Severity Index: reliability and validity in a Dutch addict population. J Subst Abuse Treat (1989) 1.33
Interleukin-17 and CD40-ligand synergistically enhance cytokine and chemokine production by renal epithelial cells. J Am Soc Nephrol (2000) 1.32
Circulating and mesangial secretory component-binding IgA-1 in primary IgA nephropathy. Kidney Int (1984) 1.32
Assessment of complement deficiency in patients with meningococcal disease in The Netherlands. Clin Infect Dis (1999) 1.30
IgA- and secretory IgA-opsonized S. aureus induce a respiratory burst and phagocytosis by polymorphonuclear leucocytes. Immunology (1987) 1.30
Changes in antibodies to C1q predict renal relapses in systemic lupus erythematosus. Am J Kidney Dis (1995) 1.29
Production and cytokine-mediated regulation of monocyte chemoattractant protein-1 by human proximal tubular epithelial cells. Kidney Int (1995) 1.29
The lectin-like domain of thrombomodulin interferes with complement activation and protects against arthritis. J Thromb Haemost (2006) 1.28
Expression of adhesion molecules in early rheumatoid synovial tissue. Clin Immunol Immunopathol (1995) 1.27
Immunoglobulin production by human peripheral lymphocytes induced by anti-C3 receptor antibodies. J Immunol (1984) 1.26
Nephelometric measurements of human IgG subclasses and their reference ranges. Ann Biol Clin (Paris) (1994) 1.25
Interleukin 2 mediates stimulation of complement C3 biosynthesis in human proximal tubular epithelial cells. J Clin Invest (1991) 1.25
Complement deficiency predisposes for meningitis due to nongroupable meningococci and Neisseria-related bacteria. Clin Infect Dis (1994) 1.24
Opsonic recognition of staphylococci mediated by cell wall peptidoglycan: antibody-independent activation of human complement and opsonic activity of peptidoglycan antibodies. J Immunol (1980) 1.21
Immunogenic properties in mice of hexasaccharide from the capsular polysaccharide of Streptococcus pneumoniae type 3. Infect Immun (1983) 1.21
Heterogeneity, polypeptide chain composition and antigenic reactivity of C3 nephritic factor. J Immunol (1978) 1.21
Presence of circulating macromolecular IgA in patients with hematuria due to primary IgA nephropathy. Am J Med (1983) 1.19
The tetracycline derivative minocycline differentially affects cytokine production by monocytes and T lymphocytes. Antimicrob Agents Chemother (1996) 1.18
Analysis of lymphoid and dendritic cells in human lymph node, tonsil and spleen. A study using monoclonal and heterologous antibodies. Virchows Arch B Cell Pathol Incl Mol Pathol (1984) 1.17
Granzyme-positive cytotoxic cells are specifically increased in early rheumatoid synovial tissue. Arthritis Rheum (1994) 1.17
Anti-endothelial cell antibodies in patients with rheumatoid arthritis complicated by vasculitis. Clin Exp Immunol (1989) 1.17
Rapamycin induces apoptosis in monocyte- and CD34-derived dendritic cells but not in monocytes and macrophages. Blood (2001) 1.16
Increased expression of IL-15 in the synovium of patients with rheumatoid arthritis compared with patients with Yersinia-induced arthritis and osteoarthritis. J Pathol (1997) 1.16
Activation of complement by human serum IgA, secretory IgA and IgA1 fragments. Mol Immunol (1988) 1.15
Effects of C-1 on the size of soluble immune aggregates and on their processing by macrophages. J Immunol (1979) 1.15
Identification of static and dynamic postural instability following traumatic brain injury. Arch Phys Med Rehabil (1996) 1.15
Proteinase 3, the major autoantigen of Wegener's granulomatosis, enhances IL-8 production by endothelial cells in vitro. J Am Soc Nephrol (1996) 1.14
Stabilization of the classical pathway C3 convertase C42, by a factor F-42, isolated from serum of patients with systemic lupus erythematosus. Immunology (1980) 1.14
Relative resistance of the F-42-stabilized classical pathway C3 convertase to inactivation by C4-binding protein. J Immunol (1980) 1.13
Immunoglobulin M-enriched human intravenous immunoglobulin prevents complement activation in vitro and in vivo in a rat model of acute inflammation. Blood (1999) 1.13
Diagnostic efficacy and prognostic value of serum procalcitonin concentration in patients with suspected sepsis. J Intensive Care Med (2008) 1.12
The role of cellular Fc and C3 receptors on the complement-dependent degradation of stable soluble immunoglobulin aggregates by normal and trypsin-treated peritoneal macrophages. Immunology (1982) 1.12
Clearance of soluble aggregates of human immunoglobulin G in healthy volunteers and chimpanzees. Clin Exp Immunol (1987) 1.12
Predictive value of IgG autoantibodies against C1q for nephritis in systemic lupus erythematosus. Ann Rheum Dis (1993) 1.12
Influence of aggregate size on the binding and activation of the first component of human complement by soluble IgG aggregates. Immunology (1982) 1.09
Selective inhibition of immune complex trapping by follicular dendritic cells with monoclonal antibodies against rat C3. Eur J Immunol (1992) 1.09
Possible involvement of terminal complement complex in active Heymann nephritis. Kidney Int (1985) 1.09
Specific inhibition of the classical complement pathway by C1q-binding peptides. J Immunol (2001) 1.09
Cognitive decline following stroke: a comprehensive study of cognitive decline following stroke. J Clin Exp Neuropsychol (1998) 1.08
Development and standardization of solid phase assays for the detection of anti-neutrophil cytoplasmic antibodies (ANCA). A report on the second phase of an international cooperative study on the standardization of ANCA assays. J Immunol Methods (1996) 1.08
The incorporation of C3 nephritic factor (C3NeF) into a stabilized C3 convertase, C3bBb(C3NeF), and its release after decay of convertase function. J Immunol (1977) 1.08
Stimulation of the intracellular killing of Staphylococcus aureus by monocytes: regulation by immunoglobulin G and complement components C3/C3b and B/Bb. J Immunol (1982) 1.08
Activation and inhibition of Hageman factor-dependent pathways and the complement system in uncomplicated bacteremia or bacterial shock. J Infect Dis (1985) 1.07
The first subcomponent of complement, C1q, triggers the production of IL-8, IL-6, and monocyte chemoattractant peptide-1 by human umbilical vein endothelial cells. J Immunol (1998) 1.07
Immunoglobulin D enhances the release of tumor necrosis factor-alpha, and interleukin-1 beta as well as interleukin-1 receptor antagonist from human mononuclear cells. Immunology (1996) 1.07
Miller Fisher anti-GQ1b antibodies: alpha-latrotoxin-like effects on motor end plates. Ann Neurol (1999) 1.07
Low polymorphonuclear cell degranulation during citrate anticoagulation: a comparison between citrate and heparin dialysis. Nephrol Dial Transplant (1997) 1.07
Dominant T-cell receptor beta-chain gene rearrangements indicate clonal expansion in the rheumatoid joint. Scand J Immunol (1990) 1.06
Significance of rheumatoid factor isotypes in seronegative rheumatoid arthritis. Rheumatol Int (1990) 1.06
Serum immune complexes containing IgA appear to predict erosive arthritis in a longitudinal study in rheumatoid arthritis. Ann Rheum Dis (1986) 1.06
Humoral immune response to influenza vaccination in patients with primary immunoglobulin A nephropathy. An analysis of isotype distribution and size of the influenza-specific antibodies. J Clin Invest (1989) 1.06
Enhanced alternative complement pathway-dependent degradation of soluble immunoglobulin aggregates by macrophages. Immunology (1981) 1.06
The clinical implications and the pathogenetic significance of circulating immune complexes in infective endocarditis. Am J Med (1981) 1.06
Endothelial cell lysis induced by lymphokine-activated human peripheral blood mononuclear cells. Eur J Immunol (1987) 1.06
Protection against meningococcal serogroup ACYW disease in complement-deficient individuals vaccinated with the tetravalent meningococcal capsular polysaccharide vaccine. Clin Exp Immunol (1998) 1.05
Heterozygous and homozygous factor H deficiency states in a Dutch family. Clin Exp Immunol (1996) 1.05
Circulating and tissue-bound immune complexes in allergic vasculitis: relationship between immunoglobulin class and clinical features. Clin Exp Immunol (1980) 1.05
Clearance and glomerular localization of preformed DNP anti-DNP immune complexes. Scand J Immunol (1979) 1.05
Distinctive roles of neutrophils and monocytes in anti-thy-1 nephritis. Am J Pathol (2000) 1.05
The bone marrow as production site of the IgA deposited in the kidneys of patients with IgA nephropathy. Clin Exp Immunol (1988) 1.04
IgG and IgA antibodies to the collagen-like region of C1q in rheumatoid vasculitis. Arthritis Rheum (1990) 1.04
Differential regulation of complement factor H and C3 production in human umbilical vein endothelial cells by IFN-gamma and IL-1. J Immunol (1990) 1.04